aristolochic acid i has been researched along with Disease Models, Animal in 50 studies
aristolochic acid I: phospholipase A inhibitor
aristolochic acid A : An aristolochic acid that is phenanthrene-1-carboxylic acid that is substituted by a methylenedioxy group at the 3,4 positions, by a methoxy group at position 8, and by a nitro group at position 10. It is the most abundant of the aristolochic acids and is found in almost all Aristolochia (birthworts or pipevines) species. It has been tried in a number of treatments for inflammatory disorders, mainly in Chinese and folk medicine. However, there is concern over their use as aristolochic acid is both carcinogenic and nephrotoxic.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to investigate the roles of aristolochic acid I (AA-I) and hypokalemia in acute aristolochic acid nephropathy (AAN)." | 7.88 | Effects of aristolochic acid I and/or hypokalemia on tubular damage in C57BL/6 rat with aristolochic acid nephropathy. ( Han, SW; Kim, J; Kim, WY; Park, MH; Yi, JH, 2018) |
| "To investigate the therapeutic effects of endothelin receptor antagonist (bosentan) and angiotensin II type 1 receptor antagonist (valsartan) on renal interstitial fibrosis of rats with chronic aristolochic acid nephropathy (CAAN)." | 7.73 | [The therapeutic effects of bosentan and valsartan on renal interstitial fibrosis of chronic aristolochic acid nephropathy]. ( Chen, YP; Dong, HR; Qiu, CB; Zhang, C, 2005) |
| "Generally, renal aging is accompanied by renal fibrosis, which is the final common pathway of chronic kidney diseases." | 5.62 | Aristolochic Acid Induces Renal Fibrosis and Senescence in Mice. ( Abe, E; Atobe, Y; Azushima, K; Funakoshi, K; Kanaoka, T; Kinguchi, S; Suzuki, T; Taguchi, S; Tamura, K; Tanaka, S; Tsukamoto, S; Uneda, K; Urate, S; Wakui, H; Yamaji, T; Yamashita, A, 2021) |
| "Bortezomib (BZM) is a proteasome inhibitor used for the treatment of multiple myeloma (MM)." | 5.46 | The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1. ( Chiga, M; Isobe, K; Mandai, S; Mori, T; Nomura, N; Rai, T; Sohara, E; Uchida, S; Yui, N; Zeniya, M, 2017) |
| "Bardoxolone methyl (BARD) is an antioxidant modulator that acts through induction of the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway." | 5.40 | Bardoxolone methyl (BARD) ameliorates aristolochic acid (AA)-induced acute kidney injury through Nrf2 pathway. ( Chen, W; Fan, J; Feng, X; Liu, X; Wang, J; Wu, J; Yang, X; Yu, X; Zeng, Y, 2014) |
| " We used the Fucci mouse in conjunction with FlowSight to identify a discrete polyploid population in proximal tubules after aristolochic acid injury." | 3.91 | Novel kidney dissociation protocol and image-based flow cytometry facilitate improved analysis of injured proximal tubules. ( Alford, CE; Flaherty, DK; Gewin, LS; Ivanova, A; Lau, KS; Manolopoulou, M; Matlock, BK; Nlandu-Khodo, S; Phillips-Mignemi, M; Simmons, AJ, 2019) |
| "This study was designed to investigate the roles of aristolochic acid I (AA-I) and hypokalemia in acute aristolochic acid nephropathy (AAN)." | 3.88 | Effects of aristolochic acid I and/or hypokalemia on tubular damage in C57BL/6 rat with aristolochic acid nephropathy. ( Han, SW; Kim, J; Kim, WY; Park, MH; Yi, JH, 2018) |
| "To investigate the therapeutic effects of endothelin receptor antagonist (bosentan) and angiotensin II type 1 receptor antagonist (valsartan) on renal interstitial fibrosis of rats with chronic aristolochic acid nephropathy (CAAN)." | 3.73 | [The therapeutic effects of bosentan and valsartan on renal interstitial fibrosis of chronic aristolochic acid nephropathy]. ( Chen, YP; Dong, HR; Qiu, CB; Zhang, C, 2005) |
| "Generally, renal aging is accompanied by renal fibrosis, which is the final common pathway of chronic kidney diseases." | 1.62 | Aristolochic Acid Induces Renal Fibrosis and Senescence in Mice. ( Abe, E; Atobe, Y; Azushima, K; Funakoshi, K; Kanaoka, T; Kinguchi, S; Suzuki, T; Taguchi, S; Tamura, K; Tanaka, S; Tsukamoto, S; Uneda, K; Urate, S; Wakui, H; Yamaji, T; Yamashita, A, 2021) |
| "Renal fibrosis is a progressive pathological process that eventually leads to end-stage renal failure with limited therapeutic options." | 1.56 | Human umbilical cord mesenchymal stem cell attenuates renal fibrosis via TGF-β/Smad signaling pathways in vivo and in vitro. ( He, D; Hu, D; Lin, T; Liu, B; Liu, X; Long, C; Shen, L; Wei, G; Xiang, H; Xu, T; Yu, Y; Zhang, D; Zhang, Y; Zhou, Y, 2020) |
| "Bortezomib (BZM) is a proteasome inhibitor used for the treatment of multiple myeloma (MM)." | 1.46 | The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1. ( Chiga, M; Isobe, K; Mandai, S; Mori, T; Nomura, N; Rai, T; Sohara, E; Uchida, S; Yui, N; Zeniya, M, 2017) |
| "Bardoxolone methyl (BARD) is an antioxidant modulator that acts through induction of the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway." | 1.40 | Bardoxolone methyl (BARD) ameliorates aristolochic acid (AA)-induced acute kidney injury through Nrf2 pathway. ( Chen, W; Fan, J; Feng, X; Liu, X; Wang, J; Wu, J; Yang, X; Yu, X; Zeng, Y, 2014) |
| "Treatment with probenecid prevented increased plasma creatinine and tubulointerstitial injuries, and reduced both the extent and the severity of ultrastructural lesions induced by aristolochic acid, such as the loss of brush border, mitochondrial edema, and the disappearance of mitochondrial crests." | 1.38 | Probenecid prevents acute tubular necrosis in a mouse model of aristolochic acid nephropathy. ( Antoine, MH; Arlt, VM; Baudoux, TE; De Prez, EG; Goujon, JM; Nortier, JL; Pozdzik, AA; Quellard, N, 2012) |
| " In the present study, the effects of a chronic intake of AA given as a single drug was evaluated through renal histology and function in rabbits." | 1.31 | Chronic aristolochic acid toxicity in rabbits: a model of Chinese herbs nephropathy? ( Bernard, AM; Cosyns, JP; Dehoux, JP; Goebbels, RM; Guiot, Y; Robert, A; van Ypersele de Strihou, C, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.00) | 18.2507 |
| 2000's | 8 (16.00) | 29.6817 |
| 2010's | 27 (54.00) | 24.3611 |
| 2020's | 14 (28.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Jiang, W | 1 |
| Xu, C | 1 |
| Xu, S | 1 |
| Su, W | 1 |
| Du, C | 1 |
| Dong, J | 1 |
| Feng, R | 1 |
| Huang, C | 1 |
| Li, J | 1 |
| Ma, T | 1 |
| Urate, S | 3 |
| Wakui, H | 3 |
| Azushima, K | 2 |
| Yamaji, T | 3 |
| Suzuki, T | 3 |
| Abe, E | 3 |
| Tanaka, S | 3 |
| Taguchi, S | 2 |
| Tsukamoto, S | 2 |
| Kinguchi, S | 3 |
| Uneda, K | 1 |
| Kanaoka, T | 1 |
| Atobe, Y | 1 |
| Funakoshi, K | 1 |
| Yamashita, A | 2 |
| Tamura, K | 3 |
| Kamimura, D | 1 |
| Sasaki, K | 1 |
| Terker, AS | 1 |
| Tang, J | 1 |
| Cao, S | 1 |
| Arroyo, JP | 1 |
| Niu, A | 1 |
| Wang, S | 1 |
| Fan, X | 1 |
| Zhang, Y | 2 |
| Bennett, SR | 1 |
| Zhang, MZ | 1 |
| Harris, RC | 2 |
| Ren, J | 1 |
| Rudemiller, NP | 1 |
| Wen, Y | 1 |
| Lu, X | 1 |
| Privratsky, JR | 1 |
| Crowley, SD | 1 |
| Chen, SM | 4 |
| Lin, CE | 2 |
| Chen, HH | 1 |
| Cheng, YF | 1 |
| Cheng, HW | 1 |
| Imai, K | 1 |
| Chang, JF | 1 |
| Hsieh, CY | 1 |
| Lu, KC | 1 |
| Chen, YW | 1 |
| Liang, SS | 1 |
| Lin, CC | 1 |
| Hung, CF | 1 |
| Liou, JC | 1 |
| Wu, MS | 1 |
| Yu, Y | 1 |
| Hu, D | 1 |
| Zhou, Y | 1 |
| Xiang, H | 1 |
| Liu, B | 1 |
| Shen, L | 1 |
| Long, C | 1 |
| Liu, X | 3 |
| Lin, T | 1 |
| He, D | 1 |
| Xu, T | 1 |
| Zhang, D | 1 |
| Wei, G | 1 |
| Zhu, Z | 1 |
| Xu, X | 2 |
| Wang, F | 1 |
| Song, Y | 2 |
| Zhu, Y | 1 |
| Quan, W | 1 |
| Zhang, X | 3 |
| Bi, C | 1 |
| He, H | 1 |
| Li, S | 1 |
| Li, X | 1 |
| Ishii, T | 1 |
| Kumagae, T | 1 |
| Kobayashi, R | 1 |
| Haruhara, K | 1 |
| Nakamura, T | 1 |
| Kobayashi, S | 1 |
| Lin, PY | 1 |
| Yang, WC | 1 |
| Huang, YS | 1 |
| Lin, TY | 1 |
| Chen, CM | 1 |
| Chen, HS | 1 |
| Lee, JA | 2 |
| Lin, F | 1 |
| Liu, Y | 1 |
| Tang, L | 1 |
| Chen, B | 2 |
| Ren, Y | 1 |
| Yang, X | 3 |
| Li, L | 1 |
| Tao, S | 1 |
| Guo, F | 1 |
| Liu, J | 1 |
| Huang, R | 1 |
| Tan, Z | 1 |
| Zeng, X | 1 |
| Ma, L | 1 |
| Fu, P | 3 |
| Succar, L | 1 |
| Pianta, TJ | 1 |
| Davidson, T | 1 |
| Pickering, JW | 1 |
| Endre, ZH | 1 |
| Zeniya, M | 1 |
| Mori, T | 1 |
| Yui, N | 1 |
| Nomura, N | 1 |
| Mandai, S | 1 |
| Isobe, K | 1 |
| Chiga, M | 1 |
| Sohara, E | 1 |
| Rai, T | 1 |
| Uchida, S | 1 |
| Honarpisheh, M | 1 |
| Foresto-Neto, O | 1 |
| Steiger, S | 1 |
| Kraft, F | 1 |
| Koehler, P | 1 |
| von Rauchhaupt, E | 1 |
| Potempa, J | 1 |
| Adamowicz, K | 1 |
| Koziel, J | 1 |
| Lech, M | 1 |
| Shao, IH | 1 |
| Chang, YH | 1 |
| Pang, ST | 1 |
| Manolopoulou, M | 1 |
| Matlock, BK | 1 |
| Nlandu-Khodo, S | 2 |
| Simmons, AJ | 1 |
| Lau, KS | 1 |
| Phillips-Mignemi, M | 1 |
| Ivanova, A | 1 |
| Alford, CE | 1 |
| Flaherty, DK | 1 |
| Gewin, LS | 1 |
| Donadei, C | 1 |
| Angeletti, A | 1 |
| Cantarelli, C | 1 |
| D'Agati, VD | 1 |
| La Manna, G | 1 |
| Fiaccadori, E | 1 |
| Horwitz, JK | 1 |
| Xiong, H | 1 |
| Guglielmo, C | 1 |
| Hartzell, S | 1 |
| Madsen, JC | 1 |
| Maggiore, U | 1 |
| Heeger, PS | 1 |
| Cravedi, P | 1 |
| Novitskaya, T | 1 |
| McDermott, L | 1 |
| Zhang, KX | 1 |
| Chiba, T | 1 |
| Paueksakon, P | 1 |
| Hukriede, NA | 1 |
| de Caestecker, MP | 1 |
| Wu, J | 2 |
| Fan, J | 2 |
| Chen, W | 1 |
| Wang, J | 2 |
| Zeng, Y | 1 |
| Feng, X | 2 |
| Yu, X | 2 |
| Neelisetty, S | 1 |
| Alford, C | 1 |
| Reynolds, K | 1 |
| Woodbury, L | 1 |
| Yang, H | 1 |
| Fogo, AB | 1 |
| Hao, CM | 1 |
| Zent, R | 1 |
| Gewin, L | 1 |
| Samarakoon, R | 1 |
| Helo, S | 1 |
| Dobberfuhl, AD | 1 |
| Khakoo, NS | 1 |
| Falke, L | 1 |
| Overstreet, JM | 1 |
| Goldschmeding, R | 1 |
| Higgins, PJ | 1 |
| Dai, XY | 1 |
| Zhou, L | 2 |
| Huang, XR | 2 |
| Lan, HY | 2 |
| Zhao, YY | 2 |
| Wang, HL | 1 |
| Cheng, XL | 1 |
| Wei, F | 1 |
| Bai, X | 2 |
| Lin, RC | 1 |
| Vaziri, ND | 2 |
| Lu, H | 1 |
| Hong, W | 1 |
| Liang, Y | 1 |
| Bai, Y | 1 |
| Chen, H | 1 |
| Cao, G | 1 |
| Chen, DQ | 1 |
| Wang, M | 1 |
| Zhang, ZH | 1 |
| Mao, JR | 1 |
| Yi, JH | 1 |
| Han, SW | 1 |
| Kim, WY | 1 |
| Kim, J | 1 |
| Park, MH | 1 |
| Wen, YJ | 1 |
| Qu, L | 1 |
| Li, XM | 1 |
| Liu, F | 1 |
| Lai, KN | 1 |
| Hamano, Y | 1 |
| Aoki, T | 1 |
| Shirai, R | 1 |
| Hatano, M | 1 |
| Kimura, R | 1 |
| Ogawa, M | 2 |
| Yokosuka, O | 1 |
| Ueda, S | 2 |
| Fragiadaki, M | 1 |
| Witherden, AS | 1 |
| Kaneko, T | 1 |
| Sonnylal, S | 1 |
| Pusey, CD | 1 |
| Bou-Gharios, G | 1 |
| Mason, RM | 1 |
| Li, YC | 1 |
| Tsai, SH | 1 |
| Chang, YM | 1 |
| Huang, TC | 1 |
| Huang, YP | 1 |
| Chang, CT | 1 |
| Li, C | 1 |
| Liang, A | 1 |
| Gao, S | 1 |
| Hui, L | 1 |
| Liu, T | 1 |
| Cao, C | 1 |
| Zhao, Y | 1 |
| Hao, R | 1 |
| Yi, Y | 1 |
| Guo, J | 1 |
| Baudoux, TE | 1 |
| Pozdzik, AA | 2 |
| Arlt, VM | 3 |
| De Prez, EG | 2 |
| Antoine, MH | 1 |
| Quellard, N | 1 |
| Goujon, JM | 1 |
| Nortier, JL | 3 |
| Sabbisetti, VS | 1 |
| Ito, K | 1 |
| Wang, C | 1 |
| Yang, L | 1 |
| Mefferd, SC | 1 |
| Bonventre, JV | 1 |
| Debelle, F | 1 |
| Nortier, J | 1 |
| De Prez, E | 1 |
| Vienne, A | 1 |
| Salmon, I | 1 |
| Phillips, DH | 2 |
| Deschodt-Lanckman, M | 1 |
| Vanherweghem, JL | 3 |
| Lebeau, C | 1 |
| Debelle, FD | 1 |
| Pozdzik, A | 1 |
| Deschodt-Lanckman, MM | 2 |
| Zhang, C | 1 |
| Chen, YP | 1 |
| Dong, HR | 1 |
| Qiu, CB | 1 |
| Salmon, IJ | 1 |
| Husson, CP | 1 |
| Decaestecker, C | 1 |
| Rogier, E | 1 |
| Bourgeade, MF | 1 |
| Lloret, S | 1 |
| Moreno, JJ | 1 |
| Cosyns, JP | 1 |
| Dehoux, JP | 1 |
| Guiot, Y | 1 |
| Goebbels, RM | 1 |
| Robert, A | 1 |
| Bernard, AM | 1 |
| van Ypersele de Strihou, C | 1 |
| Zheng, F | 1 |
| Huang, Q | 1 |
| Chitme, HR | 1 |
| Malipatil, M | 1 |
| Chandrashekhar, VM | 1 |
| Prashant, PM | 1 |
| Li, M | 1 |
| Ling, KH | 1 |
| Lam, H | 1 |
| Shaw, PC | 1 |
| Cheng, L | 1 |
| Techen, N | 1 |
| Khan, LA | 1 |
| Chang, YS | 1 |
| But, PP | 1 |
| Battu, GR | 1 |
| Parimi, R | 1 |
| Chandra Shekar, KB | 1 |
| Kwak, DH | 1 |
| Lee, JH | 1 |
| Kim, T | 1 |
| Ahn, HS | 1 |
| Cho, WK | 1 |
| Ha, H | 1 |
| Hwang, YH | 1 |
| Ma, JY | 1 |
| Sato, N | 1 |
| Takahashi, D | 1 |
| Tsuchiya, R | 1 |
| Mukoyama, T | 1 |
| Yamagata, S | 1 |
| Yoshida, M | 1 |
| Kondo, S | 1 |
| Satoh, N | 1 |
1 review available for aristolochic acid i and Disease Models, Animal
| Article | Year |
|---|---|
Recent advances in upper tract urothelial carcinomas: From bench to clinics.
Topics: Animals; Antineoplastic Agents; Aristolochic Acids; Arsenic; Carcinogens; Carcinoma, Transitional Ce | 2019 |
49 other studies available for aristolochic acid i and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Macrophage-derived, LRG1-enriched extracellular vesicles exacerbate aristolochic acid nephropathy in a TGFβR1-dependent manner.
Topics: Animals; Aristolochic Acids; Disease Models, Animal; Extracellular Vesicles; Glycoproteins; Humans; | 2022 |
Aristolochic Acid Induces Renal Fibrosis and Senescence in Mice.
Topics: Aging; Animals; Aristolochic Acids; beta-Galactosidase; Collagen; Cyclin-Dependent Kinase Inhibitor | 2021 |
Effects of tumor necrosis factor-α inhibition on kidney fibrosis and inflammation in a mouse model of aristolochic acid nephropathy.
Topics: Albuminuria; Animals; Aristolochic Acids; Collagen; Disease Models, Animal; Etanercept; Fibrosis; In | 2021 |
Macrophage interferon regulatory factor 4 deletion ameliorates aristolochic acid nephropathy via reduced migration and increased apoptosis.
Topics: Animals; Apoptosis; Aristolochic Acids; Cells, Cultured; Disease Models, Animal; DNA; DNA Mutational | 2022 |
The transcription factor Twist1 in the distal nephron but not in macrophages propagates aristolochic acid nephropathy.
Topics: Animals; Apoptosis; Aristolochic Acids; Coculture Techniques; Disease Models, Animal; Epithelial Cel | 2020 |
Effect of prednisolone on glyoxalase 1 in an inbred mouse model of aristolochic acid nephropathy using a proteomics method with fluorogenic derivatization-liquid chromatography-tandem mass spectrometry.
Topics: Animals; Aristolochic Acids; Chromatography, High Pressure Liquid; Disease Models, Animal; Female; F | 2020 |
Therapeutic Targeting of Aristolochic Acid Induced Uremic Toxin Retention, SMAD 2/3 and JNK/ERK Pathways in Tubulointerstitial Fibrosis: Nephroprotective Role of Propolis in Chronic Kidney Disease.
Topics: Animals; Aristolochic Acids; Cresols; Disease Models, Animal; Epithelial-Mesenchymal Transition; Ext | 2020 |
Human umbilical cord mesenchymal stem cell attenuates renal fibrosis via TGF-β/Smad signaling pathways in vivo and in vitro.
Topics: Animals; Aristolochic Acids; Cell Line; Coculture Techniques; Disease Models, Animal; Epithelial-Mes | 2020 |
Integrative microRNA and mRNA expression profiling in acute aristolochic acid nephropathy in mice.
Topics: Animals; Aristolochic Acids; Disease Models, Animal; Gene Expression Profiling; Gene Expression Regu | 2020 |
Tissue xanthine oxidoreductase activity in a mouse model of aristolochic acid nephropathy.
Topics: Animals; Aristolochic Acids; Disease Models, Animal; Fibrosis; Humans; Kidney Tubules; Male; Mice; R | 2021 |
Evaluation of the nephrotoxicity and safety of low-dose aristolochic acid, extending to the use of Xixin (Asurum), by determination of methylglyoxal and d-lactate.
Topics: Animals; Aristolochic Acids; Collagen; Disease Models, Animal; Drugs, Chinese Herbal; Female; Fibros | 2021 |
Rapamycin protects against aristolochic acid nephropathy in mice by potentiating mammalian target of rapamycin‑mediated autophagy.
Topics: Animals; Apoptosis; Aristolochic Acids; Autophagy; Cell Line; Disease Models, Animal; Humans; Kidney | 2021 |
Genetic and pharmacological inhibition of fatty acid-binding protein 4 alleviated inflammation and early fibrosis after toxin induced kidney injury.
Topics: Acute Kidney Injury; Animals; Aristolochic Acids; Biphenyl Compounds; Carcinogens; Disease Models, A | 2021 |
Subclinical chronic kidney disease modifies the diagnosis of experimental acute kidney injury.
Topics: Acute Kidney Injury; Adenine; Animals; Aristolochic Acids; Biomarkers; Cell Adhesion Molecules; Chem | 2017 |
The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1.
Topics: Animals; Aristolochic Acids; Bortezomib; Disease Models, Animal; Fibrosis; Kidney; Kidney Diseases; | 2017 |
Aristolochic acid I determine the phenotype and activation of macrophages in acute and chronic kidney disease.
Topics: Acute Kidney Injury; Animals; Aristolochic Acids; Cisplatin; Disease Models, Animal; Female; Fibrosi | 2018 |
Novel kidney dissociation protocol and image-based flow cytometry facilitate improved analysis of injured proximal tubules.
Topics: Acute Kidney Injury; Animals; Aristolochic Acids; Biomarkers; Cell Cycle; Cell Separation; Disease M | 2019 |
Erythropoietin inhibits SGK1-dependent TH17 induction and TH17-dependent kidney disease.
Topics: Animals; Aristolochic Acids; Cells, Cultured; Disease Models, Animal; Epoetin Alfa; Erythropoietin; | 2019 |
A PTBA small molecule enhances recovery and reduces postinjury fibrosis after aristolochic acid-induced kidney injury.
Topics: Acute Kidney Injury; Animals; Aristolochic Acids; Butyrates; Disease Models, Animal; Fibrosis; Histo | 2014 |
Bardoxolone methyl (BARD) ameliorates aristolochic acid (AA)-induced acute kidney injury through Nrf2 pathway.
Topics: Acute Kidney Injury; Animals; Aristolochic Acids; Cryoprotective Agents; Disease Models, Animal; Hem | 2014 |
Renal fibrosis is not reduced by blocking transforming growth factor-β signaling in matrix-producing interstitial cells.
Topics: Actins; Animals; Aristolochic Acids; Cells, Cultured; Collagen Type I; Disease Models, Animal; Extra | 2015 |
Loss of tumour suppressor PTEN expression in renal injury initiates SMAD3- and p53-dependent fibrotic responses.
Topics: Animals; Apoptosis; Aristolochic Acids; Cell Cycle Checkpoints; Cell Line; Cell Proliferation; Disea | 2015 |
Smad7 protects against chronic aristolochic acid nephropathy in mice.
Topics: Animals; Aristolochic Acids; Blotting, Western; Disease Models, Animal; Drugs, Chinese Herbal; Gene | 2015 |
Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress, inflammation, fibrosis, and Nrf2 dysfunction in aristolochic acid-induced nephropathy.
Topics: Animals; Aristolochic Acids; Disease Models, Animal; Fibrosis; Inflammation; Kidney; Lipids; Male; M | 2015 |
Possible role of mitochondrial injury in Caulis Aristolochia manshuriensis-induced chronic aristolochic acid nephropathy.
Topics: Animals; Apoptosis; Aristolochia; Aristolochic Acids; Biomarkers; Disease Models, Animal; Dose-Respo | 2017 |
Transforming growth factor-β1 stimulates hedgehog signaling to promote epithelial-mesenchymal transition after kidney injury.
Topics: Animals; Aristolochic Acids; Cell Line; Disease Models, Animal; Disease Progression; Epithelial-Mese | 2016 |
Metabolomics insights into activated redox signaling and lipid metabolism dysfunction in chronic kidney disease progression.
Topics: Adenine; Animals; Aristolochic Acids; Biomarkers; Disease Models, Animal; Disease Progression; Early | 2016 |
Effects of aristolochic acid I and/or hypokalemia on tubular damage in C57BL/6 rat with aristolochic acid nephropathy.
Topics: Animals; Aristolochic Acids; Disease Models, Animal; Hypokalemia; Kidney Diseases; Kidney Tubules; M | 2018 |
Ischemic injury underlies the pathogenesis of aristolochic acid-induced acute kidney injury.
Topics: Acute Disease; Animals; Aristolochia; Aristolochic Acids; Blotting, Western; Cell Nucleus; Creatinin | 2008 |
Activation of p53 promotes renal injury in acute aristolochic acid nephropathy.
Topics: Animals; Apoptosis; Aristolochic Acids; Benzothiazoles; Cells, Cultured; Disease Models, Animal; Dos | 2010 |
Low-dose darbepoetin alpha attenuates progression of a mouse model of aristolochic acid nephropathy through early tubular protection.
Topics: Animals; Apoptosis; Aristolochic Acids; Cell Proliferation; Darbepoetin alfa; Disease Models, Animal | 2010 |
Interstitial fibrosis is associated with increased COL1A2 transcription in AA-injured renal tubular epithelial cells in vivo.
Topics: Animals; Aristolochic Acids; Biomarkers; Blood Urea Nitrogen; Cadherins; Collagen Type I; Connective | 2011 |
Aristolochic acid-induced accumulation of methylglyoxal and Nε-(carboxymethyl)lysine: an important and novel pathway in the pathogenic mechanism for aristolochic acid nephropathy.
Topics: Animals; Aristolochic Acids; Creatine; Disease Models, Animal; Female; Kidney; Lysine; Mice; Mice, I | 2012 |
[Development of gastric precancerous lesion animal model].
Topics: Animals; Aristolochia; Aristolochic Acids; Disease Models, Animal; Drugs, Chinese Herbal; Humans; Ma | 2012 |
Probenecid prevents acute tubular necrosis in a mouse model of aristolochic acid nephropathy.
Topics: Animals; Aristolochic Acids; Atrophy; Biomarkers; Cell Proliferation; Cell Survival; Creatinine; Cyt | 2012 |
Novel assays for detection of urinary KIM-1 in mouse models of kidney injury.
Topics: Animals; Aristolochic Acids; Biological Assay; Biomarkers; Disease Models, Animal; Hepatitis A Virus | 2013 |
Effects of dexfenfluramine on aristolochic acid nephrotoxicity in a rat model for Chinese-herb nephropathy.
Topics: Animals; Aristolochic Acids; Autoradiography; Body Weight; Creatinine; Dexfenfluramine; Disease Mode | 2003 |
Early proximal tubule injury in experimental aristolochic acid nephropathy: functional and histological studies.
Topics: Acetylglucosaminidase; Albumins; Animals; Aristolochic Acids; Biomarkers; Carcinogens; Chromatograph | 2005 |
[The therapeutic effects of bosentan and valsartan on renal interstitial fibrosis of chronic aristolochic acid nephropathy].
Topics: Animals; Aristolochic Acids; Bosentan; Collagen Type I; Connective Tissue Growth Factor; Disease Mod | 2005 |
Patterns of interstitial inflammation during the evolution of renal injury in experimental aristolochic acid nephropathy.
Topics: Animals; Aristolochic Acids; Disease Models, Animal; Fibrosis; Kidney; Kidney Failure, Chronic; Macr | 2008 |
Effect of nonapeptide fragments of uteroglobin and lipocortin I on oedema and mast cell degranulation.
Topics: Animals; Annexin A1; Aristolochic Acids; Carrageenan; Cell Degranulation; Chlorpheniramine; Dexameth | 1994 |
Chronic aristolochic acid toxicity in rabbits: a model of Chinese herbs nephropathy?
Topics: Animals; Aristolochic Acids; Disease Models, Animal; Drugs, Chinese Herbal; Enzyme Inhibitors; Femal | 2001 |
[Establishment of model of aristolochic acid-induced chronic renal interstitial fibrosis in rats].
Topics: Animals; Aristolochic Acids; Blood Urea Nitrogen; Body Weight; Carcinogens; Chronic Disease; Creatin | 2001 |
Antiallergic activity of Aristolochia bracteolata Lank in animal model.
Topics: Anaphylaxis; Animals; Anti-Allergic Agents; Aristolochia; Dermatitis; Disease Models, Animal; Female | 2010 |
Cardiocrinum seeds as a replacement for Aristolochia fruits in treating cough.
Topics: Animals; Antitussive Agents; Aristolochia; Base Sequence; Citric Acid; Cough; Disease Models, Animal | 2010 |
In vivo and in vitro pharmacological activity of Aristolochia tagala (syn: Aristolochia acuminata) root extracts.
Topics: Acetates; Alkanes; Animals; Anti-Inflammatory Agents; Aristolochia; Calcimycin; Calcium Ionophores; | 2011 |
Aristolochia manshuriensis Kom inhibits adipocyte differentiation by regulation of ERK1/2 and Akt pathway.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Aristolochia; Cell Differentiation; Cell Survival; | 2012 |
Acute nephrotoxicity of aristolochic acids in mice.
Topics: Acute Disease; Administration, Oral; Animals; Aristolochia; Aristolochic Acids; Blood Urea Nitrogen; | 2004 |